Fmr LLC Has $853.36 Million Stake in Nektar Therapeutics (NASDAQ:NKTR)

FMR LLC grew its position in Nektar Therapeutics (NASDAQ:NKTR) by 8.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,961,520 shares of the biopharmaceutical company’s stock after purchasing an additional 2,041,954 shares during the quarter. FMR LLC owned approximately 15.00% of Nektar Therapeutics worth $853,355,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Commonwealth Equity Services LLC raised its holdings in shares of Nektar Therapeutics by 21.3% during the third quarter. Commonwealth Equity Services LLC now owns 16,320 shares of the biopharmaceutical company’s stock worth $994,000 after acquiring an additional 2,863 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Nektar Therapeutics by 20.8% during the third quarter. Bank of New York Mellon Corp now owns 1,401,029 shares of the biopharmaceutical company’s stock worth $85,406,000 after acquiring an additional 241,111 shares during the period. BlackRock Inc. raised its holdings in shares of Nektar Therapeutics by 3.7% during the third quarter. BlackRock Inc. now owns 13,121,756 shares of the biopharmaceutical company’s stock worth $799,902,000 after acquiring an additional 463,152 shares during the period. American International Group Inc. increased its stake in Nektar Therapeutics by 13.1% in the 3rd quarter. American International Group Inc. now owns 60,570 shares of the biopharmaceutical company’s stock valued at $3,692,000 after buying an additional 7,033 shares during the last quarter. Finally, Credit Suisse AG increased its stake in shares of Nektar Therapeutics by 7.4% during the 3rd quarter. Credit Suisse AG now owns 492,780 shares of the biopharmaceutical company’s stock worth $30,039,000 after purchasing an additional 33,985 shares during the last quarter. 94.63% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts recently commented on NKTR shares. ValuEngine raised shares of Nektar Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 2nd. BidaskClub raised shares of Nektar Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, April 5th. Zacks Investment Research upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $41.00 target price for the company in a research report on Tuesday, January 8th. BMO Capital Markets began coverage on shares of Nektar Therapeutics in a research report on Friday, February 22nd. They issued an “outperform” rating and a $75.00 price target for the company. Finally, Mizuho reaffirmed a “buy” rating and issued a $81.00 price objective on shares of Nektar Therapeutics in a research note on Friday, March 1st. Two analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $69.73.

Shares of Nektar Therapeutics stock traded up $0.49 during trading hours on Friday, reaching $31.68. The company’s stock had a trading volume of 3,747,607 shares, compared to its average volume of 1,496,260. Nektar Therapeutics has a one year low of $29.22 and a one year high of $92.55. The firm has a market capitalization of $5.52 billion, a price-to-earnings ratio of 8.38 and a beta of 3.05. The company has a current ratio of 17.53, a quick ratio of 17.39 and a debt-to-equity ratio of 0.14.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.13. Nektar Therapeutics had a net margin of 57.09% and a return on equity of 50.22%. The firm had revenue of $39.83 million for the quarter, compared to analyst estimates of $25.97 million. During the same period last year, the firm earned ($0.21) earnings per share. On average, research analysts forecast that Nektar Therapeutics will post -3.02 EPS for the current year.

In other news, SVP Jillian B. Thomsen sold 16,119 shares of the stock in a transaction dated Monday, February 4th. The shares were sold at an average price of $42.16, for a total value of $679,577.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Howard W. Robin sold 108,882 shares of the stock in a transaction dated Thursday, February 21st. The shares were sold at an average price of $42.19, for a total transaction of $4,593,731.58. Following the completion of the sale, the chief executive officer now owns 350,924 shares of the company’s stock, valued at approximately $14,805,483.56. The disclosure for this sale can be found here. Insiders sold 241,824 shares of company stock worth $10,249,993 over the last ninety days. Insiders own 4.31% of the company’s stock.

WARNING: “Fmr LLC Has $853.36 Million Stake in Nektar Therapeutics (NASDAQ:NKTR)” was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/21/fmr-llc-increases-position-in-nektar-therapeutics-nktr.html.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Featured Article: Conference Calls and Individual Investors

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.